<SEC-DOCUMENT>0001193125-26-332730.txt : 20260804
<SEC-HEADER>0001193125-26-332730.hdr.sgml : 20260804
<ACCEPTANCE-DATETIME>20260804160139
ACCESSION NUMBER:		0001193125-26-332730
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20260804
DATE AS OF CHANGE:		20260804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Seres Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001609809
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				274326290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273794
		FILM NUMBER:		261238370

	BUSINESS ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617 945 9626

	MAIL ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Seres Health, Inc.
		DATE OF NAME CHANGE:	20140603
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d141279d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-273794 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated
August&nbsp;15, 2023) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>103,520 Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g141279g01c01.jpg" ALT="LOGO" STYLE="width:4.14583in;height:1.54167in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering 103,520 shares of our common stock to <FONT STYLE="white-space:nowrap">BMR-Sidney</FONT> Research Campus LLC, or <FONT
STYLE="white-space:nowrap">BMR-Sidney,</FONT> pursuant to this prospectus supplement and the accompanying prospectus and a stock issuance agreement, dated as of July 31, 2026, between us and <FONT STYLE="white-space:nowrap">BMR-Sidney,</FONT> or the
Stock Issuance Agreement. The offering price per share is $4.83, which represents the closing price of our common stock on the Nasdaq Global Select Market on July 31, 2026, the date of the Stock Issuance Agreement. We will not receive any proceeds
from this offering. Pursuant to the Stock Issuance Agreement, we agreed to issue the shares being offered under this prospectus supplement and accompanying prospectus as part of the payment owed by us to
<FONT STYLE="white-space:nowrap">BMR-Sidney</FONT> pursuant to the Third Amendment to Lease and Termination Agreement, dated as of July&nbsp;31, 2026, by and between us and <FONT STYLE="white-space:nowrap">BMR-Sidney,</FONT> or the Lease Termination
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market, or Nasdaq, under the symbol &#8220;MCRB.&#8221; On August 3, 2026, the last
reported sale price of our common stock was $5.03&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. Please read
&#8220;Risk Factors&#8221; in the documents incorporated by reference into this prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is July&nbsp;31, 2026. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PROSPECTUS SUPPLEMENT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_5">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc141279_10">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ACCOMPANYING PROSPECTUS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_10">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is the prospectus supplement, including the documents incorporated by reference, which describes the specific
terms of this offering. The second part, the accompanying prospectus, including the documents incorporated by reference, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document
combined. Before you invest, you should carefully read this prospectus supplement, the accompanying prospectus, all information incorporated by reference herein and therein, as well as the additional information described under &#8220;Where You Can
Find More Information; Incorporation by Reference&#8221; on page <FONT STYLE="white-space:nowrap">S-9</FONT> of this prospectus supplement. These documents contain information you should consider when making your investment decision. This prospectus
supplement may add, update or change information contained in the accompanying prospectus. To the extent that any statement that we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any
documents incorporated by reference, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free
writing prospectuses we may provide to you in connection with this offering. We have not authorized any other person to provide you with any information that is different. If anyone provides you with different or inconsistent information, you should
not rely on it. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the offering of the common stock in certain
jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the
distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this
prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise
indicated, information contained in this prospectus supplement, the accompanying prospectus or the documents incorporated by reference, concerning our industry and the markets in which we operate, including our general expectations and market
position, market opportunity and market share, is based on information from our own management estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Management
estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. In addition, assumptions and estimates of our and our
industry&#8217;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#8220;Risk Factors&#8221; in this prospectus supplement, the accompanying prospectus and
in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended March&nbsp;31, 2026, which is incorporated by reference into this prospectus supplement. These and other important factors could cause our future
performance to differ materially from our assumptions and estimates. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
proprietary rights to trademarks used in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, which are important to our business and many of which are registered under applicable
intellectual property laws. Solely for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein are
without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest
extent under applicable law, our rights to these trademarks, service marks and trade names. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein contain additional trademarks, service
marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein
and therein are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#8217; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or
sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information about us, this offering and information appearing elsewhere in this prospectus supplement, in the accompanying
prospectus and in the documents we incorporate by reference. This summary is not complete and does not contain all the information you should consider before investing in our common stock pursuant to this prospectus supplement and the accompanying
prospectus. Before making an investment decision, to fully understand this offering and its consequences to you, you should carefully read this entire prospectus supplement and the accompanying prospectus, including the financial statements and
related notes, and the other information that we incorporate by reference into this prospectus supplement, including the risks discussed under &#8220;Risk Factors&#8221; in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
for the period ended March&nbsp;31, 2026. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seres Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Company </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage company
focused on improving patient outcomes in medically compromised populations, including oncology patients and those suffering from inflammatory and immune, or I&amp;I, diseases through discovery and development of novel live biotherapeutic product, or
LBP, candidates. We led the successful development and approval of VOWST, the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to
Soci&eacute;t&eacute; des Produits Nestl&eacute; S.A. and with certain of its affiliates in September 2024. We have established field-leading capabilities and platforms that are powered by <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-field</FONT></FONT> human data sets to advance a portfolio of products that can uniquely address diseases by targeting host pathways that are modulated by microbes in the human body, and, in particular, diseases
associated with mucosal barrier-immune interface targets. We believe clinical and nonclinical data across our programs support the development of LBPs to address unmet medical needs in oncology that can lead to interruption to patients&#8217; cancer
treatment and/or mortality (by targeting the prevention and treatment of a broad swath of infections risks faced by cancer patients and by treating immune checkpoint-related enterocolitis, or irEC), and to treat I&amp;I diseases. Our pipeline
consists of <FONT STYLE="white-space:nowrap">SER-155,</FONT> <FONT STYLE="white-space:nowrap">SER-603,</FONT> <FONT STYLE="white-space:nowrap">SER-428,</FONT> and <FONT STYLE="white-space:nowrap">SER-147,</FONT> as well as other potential candidates
in earlier development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporation Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in the State of Delaware in 2010 under the name Newco LS21, Inc. In October 2011, we changed our name to Seres Health, Inc., and in May
2015, we changed our name to Seres Therapeutics, Inc. Our principal executive offices are located at 101 Cambridgepark Drive, Cambridge, Massachusetts 02140 and our telephone number is (617) <FONT STYLE="white-space:nowrap">945-9626.</FONT> Our
website address is www.serestherapeutics.com. The information contained in, or accessible through, our website does not constitute a part of this prospectus supplement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us in this offering </P></TD>
<TD>103,520 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>10,044,781 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will not receive any proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Plan of Distribution </P></TD>
<TD>The shares being offered under this prospectus supplement and accompanying prospectus are part of the payment owed by us to <FONT STYLE="white-space:nowrap">BMR-Sidney</FONT> pursuant to the Third Amendment to Lease and Termination Agreement,
dated as of July&nbsp;31, 2026, by and between us and <FONT STYLE="white-space:nowrap">BMR-Sidney.</FONT> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#8220;MCRB&#8221; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 9,941,261 shares of our
common stock outstanding as of July&nbsp;31, 2026 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,731,363 shares of common stock issuable upon exercise of stock options outstanding as of July&nbsp;31, 2026, at
a weighted average exercise price of $39.43 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">160,540 shares of common stock issuable upon vesting of restricted stock units outstanding as of July&nbsp;31,
2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">887,251 shares of common stock reserved for issuance under our 2025 Incentive Award Plan, or the 2025 Plan, as of
July&nbsp;31, 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">102,426 shares of common stock reserved for issuance under our 2015 Employee Stock Purchase Plan, or the 2015
ESPP, as of July&nbsp;31, 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">86,826 shares of common stock reserved for issuance under our 2022 Employment Inducement Award Plan, or the 2022
Plan, as of July&nbsp;31, 2026; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32,379 shares of common stock issuable upon exercise of outstanding warrants as of July&nbsp;31, 2026.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus supplement reflects and assumes no exercise of the outstanding options and warrants and no
vesting of the outstanding restricted stock units described above. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, and the SEC filings that are incorporated by reference into this prospectus supplement and the
accompanying prospectus contain or incorporate by reference &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933, as amended, and
Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;
&#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or
&#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements contained in this prospectus supplement, the accompanying prospectus, and the SEC filings that are incorporated by reference into this
prospectus supplement and the accompanying prospectus include, but are not limited to, statements related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our status as a clinical-stage company and our expectation to incur losses in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern, our future capital needs and our need to raise additional funds;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to build a pipeline of product candidates and develop and commercialize drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our unproven, novel approach to therapeutic intervention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our limited operating history and difficulty in evaluating the success of our business to date and to assess our
future viability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive
necessary regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of completion of enrollment and availability of data from our ongoing clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect and enforce our intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal, state, and foreign regulatory requirements, including U.S. Food and Drug Administration regulation of
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions at the U.S. Food and Drug Administration and other government agencies, which could negatively impact
our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and retain key executives and attract and retain qualified personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to comply with listing rules from Nasdaq; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intended use of proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement,
the risk factors set forth under the heading &#8220;Risk Factors&#8221; in the accompanying prospectus and incorporated by reference in this prospectus supplement and the accompanying prospectus. These forward-looking statements speak only as of the
date of this prospectus supplement. Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect new information, events or circumstances after the date of this
prospectus supplement or to reflect the occurrence of unanticipated events. In light of these risks and uncertainties, the forward-looking events and circumstances described in this prospectus supplement may not occur and actual results could differ
materially from those anticipated or implied in the forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds in connection with the offering of common stock described in this prospectus supplement. The total value of the shares being
offered under this prospectus supplement and accompanying prospectus is $500,001.60. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund the
development and growth of our business. We do not anticipate paying any dividends on our capital stock in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our Board of Directors after
considering our financial condition, results of operations, capital requirements, business prospects and other factors the Board of Directors deems relevant, and subject to the restrictions contained in any future financing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BMR-Sidney&#8217;s</FONT> ownership interest in our common stock will be immediately diluted to the extent of the difference
between the offering price per share and the as adjusted net tangible book value per share of our common stock after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31,
2026, we had a net tangible book value of approximately $26.5&nbsp;million, or $2.76 per share of common stock. Our net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of common
stock outstanding at March&nbsp;31, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the issuance and sale by us of 103,520 shares of common stock in this offering, our as
adjusted net tangible book value as of March&nbsp;31, 2026 would have been approximately $26.5&nbsp;million, or approximately $2.73 per share. This amount represents an immediate decrease in as adjusted net tangible book value of $0.03 per share to
our existing stockholders and an immediate dilution in as adjusted net tangible book value of approximately $2.10 per share to <FONT STYLE="white-space:nowrap">BMR-Sidney.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dilution per share to <FONT STYLE="white-space:nowrap">BMR-Sidney</FONT> is determined by subtracting as adjusted net tangible book value per share after this
offering from the offering price per share. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of March&nbsp;31, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Decrease) in as adjusted net tangible book value per share attributable to this offering</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to <FONT STYLE="white-space:nowrap">BMR-Sidney</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 9,592,326 shares of our common stock outstanding as of March&nbsp;31, 2026, and
excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,642,883 shares of common stock issuable upon exercise of stock options outstanding as of March&nbsp;31, 2026,
at a weighted average exercise price of $45.73 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">185,120 shares of common stock issuable upon vesting of restricted stock units outstanding as of March&nbsp;31,
2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">54,252 shares of common stock reserved for issuance under our 2025 Plan as of March&nbsp;31, 2026; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">102,426 shares of common stock reserved for issuance under our 2015 ESPP as of March&nbsp;31, 2026;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">86,731 shares of common stock reserved for issuance under our 2022 Plan, as of March&nbsp;31, 2026; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32,379 shares of common stock issuable upon exercise of outstanding warrants as of March&nbsp;31, 2026.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent any of the outstanding options or warrants described above are exercised or outstanding restricted stock units described
above vest, there may be further dilution to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2026, we entered into the Stock Issuance Agreement with <FONT STYLE="white-space:nowrap">BMR-Sidney</FONT> pursuant to which we agreed to
issue the shares being offered under this prospectus supplement and accompanying prospectus as part of the payment owed by us to <FONT STYLE="white-space:nowrap">BMR-Sidney</FONT> pursuant to the Lease Termination Agreement. BMR-Sidney served as our
landlord under a lease agreement dated November 11, 2015, as amended, which is being terminated pursuant to the Lease Termination Agreement. BMR-Sidney is not an affiliate of the Company. This issuance is not being made for capital-raising purposes.
Rather, the shares are being issued as a portion of the total amount owed by us to BMR-Sidney in connection with the termination of our lease at the Sidney Research Campus pursuant to the Lease Termination Agreement. Under the Stock Issuance
Agreement, BMR-Sidney may assign its rights thereunder to an affiliate, and the shares offered hereby may be issued to BMR-Sidney or such affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No
underwriting discounts, commissions, or other compensation will be paid to any person in connection with the issuance of the shares. No underwriter, broker, dealer, or agent is participating in this offering. Each party is responsible for its own
costs and expenses in connection with this transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no lock-up agreements or other contractual restrictions on BMR-Sidney&#8217;s ability
to sell the shares following issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this prospectus supplement by reference to the Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2025 have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company&#8217;s ability to continue as a
going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc141279_10"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Available Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file electronically reports, proxy statements and other information with the SEC. The SEC maintains a web site that contains reports, proxy and information
statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
web site address is www.serestherapeutics.com. The information on our web site, however, is not, and should not be deemed to be, a part of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC and do not contain all of the
information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided above. Other documents establishing the terms of the offered securities are or may be filed as exhibits to the registration
statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a
more complete description of the relevant matters. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation by Reference </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC&#8217;s rules allow us to &#8220;incorporate by reference&#8221; information into this prospectus supplement and the accompanying prospectus, which
means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus supplement and the accompanying prospectus,
and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes
of this prospectus supplement and the accompanying prospectus to the extent that a statement contained in this prospectus supplement or the accompanying prospectus modifies or replaces that statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference the following information or documents that we have filed with the SEC: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312526085368/d13425d8k.htm">March&nbsp;2,
 2026</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312526108482/d47103d8k.htm">March&nbsp;
16, 2026</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312526251548/d100982d8k.htm">June&nbsp;
1, 2026</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312526258366/d156701d8k.htm">June&nbsp;
5, 2026</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312526298005/d130829d8k.htm">July&nbsp;8, 2026</A>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312526205434/mcrb-20260331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> filed with the SEC on May&nbsp;5, 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312526103276/mcrb-20251231.htm#signatures">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2025, filed with the SEC on March&nbsp;12, 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our Common Stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1609809/000119312515230190/d816354d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, dated and filed with the SEC on June&nbsp;22, 2015, and any amendment or report filed with the SEC for the purpose of updating the description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus supplement and accompanying prospectus all reports and other documents we subsequently file with the SEC
pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, between the date of this prospectus supplement and the termination of the offering of the securities described in this prospectus supplement. We are
not, however, incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed &#8220;filed&#8221; with the SEC, including any information furnished pursuant to Items 2.02 or
7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or related exhibits furnished pursuant to Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The reports and documents specifically listed above or filed in the future (excluding
any information furnished to, rather than filed with, the SEC) are deemed to be part of this prospectus supplement and accompanying prospectus from the date of the filing of such reports and documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a free copy of any of the documents incorporated by reference in this prospectus supplement
(other than exhibits, unless they are specifically incorporated by reference in the documents) by writing or telephoning us at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seres Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>101 Cambridgepark Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, MA 02140 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">945-9626</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus supplement and
the accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g141279g04a04.jpg" ALT="LOGO" STYLE="width:1.92708in;height:0.729167in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SERES THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$300,000,000 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This
prospectus provides you with a general description of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we offer and sell securities, we will provide a
supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to that
offering. You should carefully read this prospectus and the applicable prospectus supplement before you invest in any of our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters,
dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or
discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled &#8220;About this Prospectus&#8221; and
&#8220;Plan of Distribution&#8221; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#8220;<A HREF="#toc141279_4">RISK FACTORS</A>&#8221; ON PAGE&nbsp;5 OF THIS PROSPECTUS
AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;MCRB.&#8221; On August 7, 2023, the last reported sale
price of our common stock on the Nasdaq Global Select Market was $4.61 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor
any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is August 15, 2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_10">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc141279_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a
&#8220;shelf&#8221; registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a total dollar amount of $300,000,000 as described in this prospectus. Each time that we
offer and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free
writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus with respect
to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable.
Before purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together with the additional information described under the heading
&#8220;Where You Can Find More Information; Incorporation by Reference.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any
information or to make any representations other than those contained in this prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should
assume that the information appearing in this prospectus and the applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is
accurate only as of the date of that free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial
condition, results of operations and prospects may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry
statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have
not independently verified this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus, any prospectus supplement or any applicable free writing prospectus may
involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; contained in this prospectus, the applicable prospectus
supplement and any applicable free writing prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we refer to &#8220;Seres,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; in this prospectus,
we mean Seres Therapeutics, Inc. and its consolidated subsidiaries, unless otherwise specified. When we refer to &#8220;you,&#8221; we mean the potential holders of the applicable series of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have proprietary rights to trademarks that are used in this prospectus and the documents incorporated by reference herein, which are
important to our business and many of which are registered under applicable intellectual property laws. Solely for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus and the documents incorporated by
reference herein may be without the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;and&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&nbsp;symbols, but such references are not intended to indicate, in any way,
that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, service marks and trade names. This prospectus and the documents incorporated by reference herein contain additional trademarks, service marks and
trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this prospectus and the documents incorporated by reference herein are, to our knowledge, the property of their
respective owners. We do not intend our use or display of other companies&#8217; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_2"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file
reports, proxy statements and other information with the SEC. The SEC maintains a web site that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of
that website is <I>http://www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our web site address is <I>http://www.serestherapeutics.com</I>. The information on our web
site, however, is not, and should not be deemed to be, a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part
of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the indenture and other
documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement
about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a
copy of the registration statement through the SEC&#8217;s website, as provided above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by Reference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC&#8217;s rules allow us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will
automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a
statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been
filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000095017023006374/mcrb-20221231.htm">March&nbsp;7, 2023</A>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000095017023014419/mcrb-20230425.htm">April&nbsp;25,
 2023</A>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2023 and June 30, 2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000095017023019222/mcrb-20230331.htm">May&nbsp;
9, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000095017023039439/mcrb-20230630.htm">August 8, 2023</A>, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312523002405/d436852d8k.htm">January&nbsp;5,
 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312523120045/d200991d8k.htm">April&nbsp;
27, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312523173803/d518244d8k.htm">June&nbsp;
23, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1609809/000119312523176795/d506361d8k.htm">June&nbsp;28, 2023</A>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our Common Stock contained in our Registration Statement on Form <FONT
STYLE="white-space:nowrap">8-A,</FONT> dated and filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1609809/000119312515230190/d816354d8a12b.htm">June&nbsp;22, 2015</A>, and any amendment or report filed with the SEC for the
purpose of updating the description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All reports and other documents we subsequently file pursuant to
Section&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the &#8220;Exchange Act&#8221; in this prospectus, prior to the termination of this offering, including all such documents we may file
with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such
reports and documents. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed &#8220;filed&#8221; with the SEC, including our stock performance
graph or any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following
address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Seres Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 Sidney Street &#8211; 4th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cambridge, MA 02139 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(617) <FONT
STYLE="white-space:nowrap">945-9626</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exhibits to the filings will not be sent, however, unless those exhibits have specifically
been incorporated by reference in this prospectus or any accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Company </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
commercial-stage microbiome therapeutics company focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a
disrupted microbiome to a <FONT STYLE="white-space:nowrap">non-disease</FONT> state. Our first drug, VOWST (fecal microbiota spores, live-brpk), formerly called <FONT STYLE="white-space:nowrap">SER-109,</FONT> was approved by the U.S. Food and Drug
Administration, or FDA, on April&nbsp;26, 2023 to prevent recurrence of <I>Clostridioides difficile</I> infection, or CDI, in patients 18 or older following antibacterial treatment for recurrent CDI. We launched VOWST in the United States with our
collaborator, Nestl&eacute; Health Science, in June 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Building upon VOWST, we are developing therapeutic candidates, such as <FONT
STYLE="white-space:nowrap">SER-155,</FONT> to specifically target infections and antimicrobial resistance. <FONT STYLE="white-space:nowrap">SER-155,</FONT> a microbiome therapeutic candidate consisting of a
<FONT STYLE="white-space:nowrap">16-strain</FONT> consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections, as well as induce immune tolerance responses to reduce the incidence of
Graft versus Host Disease (&#8220;GvHD&#8221;) in patients undergoing allogeneic hematopoietic stem cell transplantation. Gastrointestinal microbiome data from the first 100 days of <FONT STYLE="white-space:nowrap">SER-155</FONT> Phase 1b open-label
study cohort 1 showed the successful engraftment of <FONT STYLE="white-space:nowrap">SER-155</FONT> bacterial strains, and a substantial reduction in the cumulative incidence of pathogen domination, a biomarker associated with the risk of serious
enteric infections and resulting bloodstream infections, as well as GvHD. The tolerability profile observed was favorable, with no serious adverse events attributed to <FONT STYLE="white-space:nowrap">SER-155</FONT> administration. Enrollment in the
placebo-controlled cohort 2 portion of the study is ongoing and <FONT STYLE="white-space:nowrap">100-day</FONT> topline results are anticipated in <FONT STYLE="white-space:nowrap">mid-2024.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also progressing additional preclinical stage programs to evaluate how microbiome therapeutics may reduce incidence of infections in
indications such as cancer neutropenia, chronic liver disease, solid organ transplant, and antimicrobial resistant infections more broadly in settings of high-risk such as intensive care units. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in the State of Delaware in 2010 under the name Newco LS21, Inc. In October 2011, we changed our name to Seres Health, Inc., and in May 2015, we changed our name to Seres Therapeutics, Inc. Our principal executive offices are located at
200 Sidney Street, Cambridge, Massachusetts 02139 and our telephone number is (617) <FONT STYLE="white-space:nowrap">945-9626.</FONT> Our website address is www.serestherapeutics.com. The information contained in, or accessible through, our website
does not constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. Before deciding
whether to invest in our securities, you should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the
Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement and any applicable free writing prospectus. The occurrence of any of these risks might cause you to lose all or part of your investment in the
offered securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock and certain provisions of our restated certificate of incorporation and amended and restated
bylaws are summaries and are qualified in their entirety by reference to the applicable provisions of our restated certificate of incorporation and amended and restated bylaws, which have been publicly filed with the Securities and Exchange
Commission. We encourage you to read our restated certificate of incorporation, our amended and restated bylaws and the applicable provisions of the General Corporation Law of the State of Delaware for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">240,000,000 shares of common stock, par value $0.001 per share; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,000,000 shares of preferred stock, par value $0.001 per share. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights.
</I>Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality
of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes
cast by the stockholders present or represented and voting on such matter. Our restated certificate of incorporation and amended restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the
holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our
restated certificate of incorporation. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we
may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Rights Upon Liquidation. </I>In the event of our liquidation or dissolution, the holders of
common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Rights. </I>Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and
privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock are
entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock. We have never declared or paid any cash dividends on our capital stock. We do
not intend to pay cash dividends for the foreseeable future. We currently expect to retain all future earnings, if any, for use in the development, operation and expansion of our business. Any determination to pay cash dividends in the future will
depend upon, among other things, our results of operations, plans for expansion, tax considerations, available net profits and reserves, limitations under law, financial condition, capital requirements and other factors that our board of directors
considers to be relevant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of our restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred
stock in one or more series without stockholder approval. Our board of directors has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences,
of each series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of authorizing our board of directors to issue preferred stock and determine its rights
and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes,
could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. There are no shares of preferred stock outstanding, and we have no
present plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our restated certificate of incorporation and our amended and restated bylaws could make the following
transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it
more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interest, including transactions which provide for payment of a premium over the market price for our
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of
an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Undesignated Preferred Stock</I>. The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000
shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to effect a change in control of us. These and other provisions may have the effect of
deferring hostile takeovers or delaying changes in control or management of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder Meetings</I>. Our amended and
restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board
of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Requirements for Advance Notification of Stockholder Nominations and Proposals</I>. Our amended and restated bylaws
establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of
directors or a committee of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Elimination of Stockholder Action by Written Consent</I>. Our restated certificate
of incorporation eliminates the right of stockholders to act by written consent without a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Staggered Board</I>. Our board of
directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from
making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors.</I> Our restated certificate of incorporation provides that no member of our board of directors may be removed from
office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of stock
entitled to vote in the election of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholders Not Entitled to Cumulative Voting.</I> Our restated certificate of
incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the
directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Statute.</I> We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware, which
prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders
unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person
who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221;
includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this law may have an anti-takeover effect with respect to transactions not approved in advance by the board
of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Choice of Forum.</I> Our restated certificate of incorporation provides that, unless we consent in writing to the
selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a
fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of
Delaware or our restated certificate of incorporation or amended and restated bylaws; or (4)&nbsp;any action asserting a claim governed by the internal affairs doctrine. In addition, our bylaws provide that the federal district courts of the United
States are the exclusive forum for any complaint raising a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to
have consented to these choice of forum provisions. It is possible that a court of law could find the choice of forum provisions contained in our restated certificate of incorporation or bylaws to be inapplicable or unenforceable if challenged in a
proceeding or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment of Restated Certificate of Incorporation. </I>The amendment of any of the above provisions in our
restated certificate of incorporation, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of stock entitled to vote thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions
of Delaware law, our restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the
market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions
could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement or free writing
prospectus, summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a
supplement to this prospectus. We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities
described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and
may be issued in one or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture between us and a trustee to be named in the
applicable indenture. We have summarized select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that
may be important to you. In the summary below, we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings
specified in the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this section only, &#8220;Seres,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;
refer to Seres Therapeutics, Inc., excluding our subsidiaries, unless expressly stated or the context otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or
determined in the manner provided in a resolution of our board of directors, in an officer&#8217;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus
supplement relating to such series (including any pricing supplement or term sheet). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue an unlimited amount of debt securities
under the indenture that may be in one or more series with the same or various maturities, at par, at a premium, or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating
to any series of debt securities being offered, the aggregate principal amount and the following terms of the debt securities, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and ranking of the debt securities (including the terms of any subordination provisions);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal of the securities of the series is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates
(including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable
and any regular record date for the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the
method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period or periods within which, the price or prices at which and the terms and conditions upon which we may
redeem the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part,
pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities, which may be United States Dollars or any foreign currency,
and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal of, premium and
interest on the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or
currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities
will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture
with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with
respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect
to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if
applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as
it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including
the terms of subordination, if any, of such guarantees. (Section 2.2) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for an amount less than their stated principal
amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any
of these debt securities in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a
foreign currency or currencies or a foreign currency unit or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will
provide you with information on the restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in
the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company, or the
Depositary, or a nominee of the Depositary (we will refer to any debt security represented by a global debt security as a &#8220;book-entry debt security&#8221;), or a certificate issued in definitive registered form (we will refer to any debt
security represented by a certificated security as a &#8220;certificated debt security&#8221;) as set forth in the applicable prospectus supplement. Except as set forth under the heading &#8220;Global Debt Securities and Book-Entry System&#8221;
below, book-entry debt securities will not be issuable in certificated form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certificated Debt Securities. You may transfer or exchange
certificated debt securities at any office we maintain for this purpose in accordance with the terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require
payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange. (Section 2.7) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium and interest on certificated
debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new
holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will be deposited
with, or on behalf of, the Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see &#8220;Global Securities.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the
applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities. (Article IV) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a
Change of Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any
provisions which may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) which could adversely
affect holders of debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to any
person (a &#8220;successor person&#8221;) unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving entity or the successor person (if other than Seres) is a corporation, partnership, trust or
other entity organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be
continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part
of its properties to us. (Section 5.1) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Event of Default&#8221; means with respect to any series of debt securities, any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and
continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the <FONT STYLE="white-space:nowrap">30-day</FONT> period);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of any security of that series at its maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a
covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or
Seres and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Seres;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other Event of Default provided with respect to debt securities of that series that is described in the
applicable prospectus supplement. (Section 6.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Event of Default with respect to a particular series of debt
securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an
acceleration under the indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide the trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such
Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action we are taking or propose to take in respect thereof. (Section 6.1) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the
holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if the
debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if any, on all debt securities of that series. In the case of an Event of
Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable
without any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to debt securities of any series has
been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all
Events of Default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and interest, if any, with respect to debt securities of that series, have been cured or waived as provided in the indenture. (Section
6.2) We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the
occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that the trustee may refuse to perform any duty or exercise any of its rights
or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to
certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the
trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section 6.12) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No
holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made
written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the
outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive
payment of the principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section&nbsp;6.8) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the
indenture. (Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each Securityholder of the
securities of that series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may
withhold notice to the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that
withholding notice is in the interest of the holders of those debt securities. (Section 7.5) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any
debt security: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with covenants in the indenture described above under the heading &#8220;Consolidation, Merger and Sale
of Assets&#8221;; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated securities in addition to or in place of certificated securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add guarantees with respect to debt securities of any series or secure debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to surrender any of our rights or powers under the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add covenants or events of default for the benefit of the holders of debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the applicable procedures of the applicable depositary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to
or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act. (Section 9.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also modify and amend the indenture with the consent of the holders of at
least a majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then
outstanding if that amendment will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of,
or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission
of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such
acceleration); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of or premium or interest on any debt security payable in currency other than that stated in
the debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security. (Section 9.3) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any
series may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of the outstanding debt securities of any series may on
behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt
security of that series; provided, however, that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that
resulted from the acceleration. (Section 6.13) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we
may be discharged from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and/or U.S. government
obligations or, in the case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal
in accordance with their terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of
principal, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received
from, or there has been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable United States federal income tax law, in either case to the effect
that, and based thereon such opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit, defeasance and discharge and
will be subject to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. (Section 8.3) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt
securities, upon compliance with certain conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may omit to comply with the covenant described under the heading &#8220;Consolidation, Merger and Sale of
Assets&#8221; and certain other covenants set forth in the indenture, as well as any additional covenants which may be set forth in the applicable prospectus supplement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to
the debt securities of that series (&#8220;covenant defeasance&#8221;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide
money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments
in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to United States federal income tax on the same amounts and in the same
manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred. (Section 8.4) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Personal Liability of Directors, Officers, Employees or Securityholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our past, present or future directors, officers, employees or securityholders, as such, will have any liability for any of our
obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and
release is part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against
public policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities)
irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions
contemplated thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of
the debt securities (by their acceptance of the debt securities) irrevocably submit to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide
that service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#8217;s address set forth in the indenture will be effective service of process for any suit, action
or other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the
laying of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.
(Section 10.10) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants
independently or together with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors
or a warrant agent. The following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable
to a particular series of warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well
as the complete warrant agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The particular terms of any issue of
warrants will be described in the prospectus supplement relating to the issue. Those terms may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase
such shares and the price at which such number of shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and
voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common
stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">United States Federal income tax consequences applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange,
exercise and settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to vote, consent or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as shareholders with respect to any meeting of shareholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as shareholders of Seres. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common
stock at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to
the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of
transfer and exercise them at the corporate trust office of the warrant agent or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised, the holder of the warrants will not have any rights of holders of the
debt securities that can be purchased upon exercise, including any rights to receive payments of principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants to purchase
common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders of the underlying common stock or preferred stock, including any rights to receive dividends or payments upon any liquidation, dissolution
or winding up on the common stock or preferred stock, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_9"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may
evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and
address of the unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description,
together with the additional information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing
prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and
provisions and we will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered
under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus
supplement, including, without limitation, the following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain United States federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_10"></A>GLOBAL SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry, Delivery and Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
indicate differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or global securities, or, collectively, global
securities. The global securities will be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as depositary, or DTC, and registered in the name of Cede&nbsp;&amp; Co., the nominee of DTC. Unless and until it is
exchanged for individual certificates evidencing securities under the limited circumstances described below, a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by the
depositary or its nominee to a successor depositary or to a nominee of the successor depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC has advised us that it is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited-purpose trust company organized under the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#8220;banking organization&#8221; within the meaning of the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#8220;clearing corporation&#8221; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#8220;clearing agency&#8221; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants
of securities transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#8217; accounts, thereby eliminating the need for physical movement of securities certificates.
&#8220;Direct participants&#8221; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust&nbsp;&amp;
Clearing Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated
subsidiaries. Access to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules
applicable to DTC and its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases of securities under the DTC system must be made by or through
direct participants, which will receive a credit for the securities on DTC&#8217;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and
indirect participants&#8217; records. Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their
transactions, as well as periodic statements of their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the
books of participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of
DTC&#8217;s partnership nominee, Cede&nbsp;&amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other nominee
will not change the beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#8217;s records reflect only the identity of the direct participants to whose accounts the securities are
credited, which may or may not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the securities are in book-entry form, you will receive payments and may transfer
securities only through the facilities of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands
in respect of the securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct
participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redemption notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC&#8217;s practice is
to determine by lot the amount of the interest of each direct participant in the securities of such series to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither DTC
nor Cede&nbsp;&amp; Co. (or such other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the
consenting or voting rights of Cede&nbsp;&amp; Co. to those direct participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the registered
owner of such securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated form under the limited circumstances described below and unless if otherwise provided in the description of the applicable
securities herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in
writing to the applicable trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redemption proceeds, distributions and dividend payments on the securities will be made to Cede&nbsp;&amp; Co., or such other nominee as may
be requested by an authorized representative of DTC. DTC&#8217;s practice is to credit direct participants&#8217; accounts upon DTC&#8217;s receipt of funds and corresponding detail information from us on the payment date in accordance with their
respective holdings shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered
in &#8220;street name.&#8221; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend
payments to Cede&nbsp;&amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility, disbursement of payments to direct participants is the responsibility of DTC, and disbursement of payments to
the beneficial owners is the responsibility of direct and indirect participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except under the limited circumstances described below,
purchasers of securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise
any rights under the securities and the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions may require that some purchasers of securities take
physical delivery of securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing its services as securities depositary with respect to the securities at any time by giving reasonable notice to
us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be printed and delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, beneficial owners of a particular series of securities generally will not
receive certificates representing their ownership interests in those securities. However, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities
representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90 days of the notification to us or
of our becoming aware of DTC&#8217;s ceasing to be so registered, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an Event of Default has occurred and is continuing with respect to such series of securities,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">we will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any
beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the names that the depositary directs. It is
expected that these directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests in the global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Euroclear and Clearstream </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so provided in the applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A., which we
refer to as &#8220;Clearstream,&#8221; or Euroclear Bank S.A./N.V., as operator of the Euroclear System, which we refer to as &#8220;Euroclear,&#8221; either directly if you are a participant in Clearstream or Euroclear or indirectly through
organizations which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their respective participants through customers&#8217; securities accounts in the names of Clearstream and Euroclear,
respectively, on the books of their respective U.S. depositaries, which in turn will hold such interests in customers&#8217; securities accounts in such depositaries&#8217; names on DTC&#8217;s books. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clearstream and Euroclear are securities clearance systems in Europe. Clearstream and Euroclear hold securities for their respective
participating organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their accounts, thereby eliminating the need for physical movement of
certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments, deliveries, transfers, exchanges, notices and other matters relating to beneficial interests in global securities
owned through Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and other participants in DTC, on the other hand, are also subject to
DTC&#8217;s rules and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors will be able to make and receive through Euroclear and Clearstream payments, deliveries,
transfers and other transactions involving any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and
other institutions are open for business in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cross-market transfers between participants in DTC, on the one hand, and
participants in Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with the DTC&#8217;s rules on behalf of Euroclear or Clearstream, as the case may be, by their respective U.S. depositaries; however, such
cross-market transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of
such system. Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final settlement on its behalf by delivering or receiving
interests in the global securities through DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement. Participants in Euroclear or Clearstream may not deliver
instructions directly to their respective U.S. depositaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to time zone differences, the securities accounts of a participant in Euroclear or
Clearstream purchasing an interest in a global security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing
day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in
Euroclear or Clearstream to a direct participant in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream
following DTC&#8217;s settlement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been
obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This information has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely
within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent of ours or of the trustee has any control over those entities and none of us takes any responsibility for their activities. You are
urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters. In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any
obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time. Neither we nor any agent of ours will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear
or their respective participants of these or any other rules or procedures governing their respective operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods or through underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the
method of distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers
to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as
principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with
the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we or the
purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best
efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or
commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the
meaning of the Securities Act of 1933, as amended, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into
agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for
certain expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any common stock will be listed on the Nasdaq Global Select Market, but any other securities may or may not be listed
on a national securities exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include
over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by
making purchases in the open market or by exercising </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing
penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to
stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In
addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with
those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others
to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will
be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third
party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection
with a concurrent offering of other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in
respect of any given offering will be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage
in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on
behalf of Seres Therapeutics, Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc141279_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements and management&#8217;s assessment of the effectiveness of internal control over financial reporting (which is
included in Management&#8217;s Annual Report on Internal Control Over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2022 have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers
LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>103,520 Shares </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g141279g01c01.jpg" ALT="LOGO" STYLE="width:4.14583in;height:1.54167in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:200pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;31, 2026 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g141279g01c01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g141279g01c01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1H^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &B$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H_\  $0@!SP3< P$B  (1 0,1 ?_$ !P  0 !!0$!
M   ! @4&!P@$ __$ %80  $# @0"!00*#P0(!P$!  $  @,$$042(3$&00<3
M(E%A%#)QT1<C-8&1DI2QLL$(%18S-#9"4E5R<W2ATN%35&*")"4F0V.#D[-$
M162$HL+P\:/_Q  : 0$  @,!                 00" P4&_\0 +1$!  ("
M @(!! $$ @(#      $" Q$$(1(Q0043(E$R%"-A@9&Q0J%2<<'_V@ , P$
M A$#$0 _ .J41$!$1 1$0$1$ :H@T10"(BD02!N4OW*F07(4M! 1!KNFI2Q_
M.46(V*C251-M>2@D$;JASPQIZQ[0/$V5OK<6I:=OWV.X/)X644F?2)F(7(.
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MG:6NOONJ@-U38 [*427[]$!!V*I>[2UBI8+"_>H0J3DET!4I0%*(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M'7!Y+Z#TJKZ;1$12"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M1=K8#GZ$%UTVS:A";;BX0-%[G=5$7%B@Y^^R"-_(?WB;ZEIIK>:W)]D)8"@
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M6FXNFX_VB(^465-M2JKJ"5/4^D]J5!4J-U,1/RGM25&BD[J"$F?TF)A&Y39
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M9SW_ #=5E3DQGZAZ'#Q:8,<:A]HZ6:=CIH6@Q1:R$FUE\S<CL;+;/#G#,46
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M]*Y_S!IT:'%1?(0YIU'<@[&P'B[#,;8'T/7V+<W;9;2]N]9 YP&ZXEI:^MA
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MWI77_'_XEXU^[/\ F7(&(_ATWI0>47RFVZEKLUP_6RANC20IS$<D%-Q?*%(
M;YW/93EN,RACKWOR03HFB7"C3O038)V>Y4Z=ZG3O0+A-+IIWIIWH!<-F:'FI
M#'$6)%U2XVM;6ZK&41Y'.LZZ#L7@,YN$L&#M<M# /_\ ,+(0L?X"&7A'!K<Z
M&#_MA9 $!$1!!L=#S7EK*:&LA=!*S,T @@DCP7J+;N![E*#GGI*Z,74#)Z_
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M+K,<\G?]5=26TLIUY(.(Z^@FHI'1U SEIM=H-EXF6)L!;TKMS$<-AKX\DSI
M+W[) Y6[EJSB[HBH:BFDJ,/\OFK&,:V-AE8 >UKNT<B>:#G@@C0%0VXW*O\
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MY3K:\X7TA4]34,AEH*B(N)[4C@ -+JZ/XKIF7=U9>#R#QHL'Q##F5QS2YLP
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M@'N'AW[M']$(/<B(@(B("(B B(@(B(")K=4YKN+1N$%2(A* BB]FDN4@W *
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M:R-AL,Q&I.O-=,4TS9XL\8(;>VJ"NP-C?95!4BS3;O50[@@L''_XE8U^[/\
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M6!M]3JM=*S,=.7')\9U$L*XOX>P^B<&4E,R,!Y&CG'2WB5C+:9C)!V1\*O\
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M*V.PES 3H4#0&P4I;6Z( T&B*+:W6.\78K)AL,3A&TDY[9KZVL@R-0"'>\L
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M_4O$=7(YOG"0G^*NU%Q7B%!3Y8##:]^TR_UH-P7 YA3<'8K5'W;XLX7O3_\
M3_JH''&,-[0\G[OO?]4&UP0=B"I!6#<(<05V)3Y9^JMG [+;<EG#;\T%CXY/
M^RU=Z&?3:M11@=?$;6.8?.MN<<Z<+5SAN SZ86H8GVE:Z3S00=$&\<.-X?"Y
M7J[Q98=AO&F%109))9 ZY.D97UEXVPX F.5_A>(H,J R^>\6\5JKCZN94XA
MV,AV3,TV=>VJ]N*\;2R!PHW,+M+9HRK'@V"U.*5PE>T%CI07V<!N;E!D?1Q0
MN97"K/FOA</-_P 0Y^\MB*WX+AL>'4444>;L C4WW)*]Y O?N02H<0 ;D#TI
M<;JW\05(I,(J*B]L@'*_Y0'UH-=\>X@:RI-.U[@()GCS[@\M KET<4.8,K2P
M7:][=6Z[=_OK#ZAPKL6>[<RS7[MW+;G"U#]K\,,-B/;"[4W[D'VQRF%1A-8T
M@%Q@>&W%[7:5INICDH*QT7::X :CL[K>CVA['-.Q%BM6\?4!AQ:6:,=BS!J?
M!!GW#E8VLPZ/*;EC&-/:OR5T&CCW+7O1QB+8^O@>>T^1H&G@5L($$Z(%M;K
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M X<7'_2:NXY7;ZEFEM4  )(&Z"QX7P[340&5\KB"?.MZE>!V&AL8!L+%?1
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(!$1 1$0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g141279g04a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g141279g04a04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %PJ^6)@X0DE-! 0      !D< @   @  ' )0  U386-H:6X@2W5M87(V
M #A"24T$)0      $&6:C.E^<(T%=.G0IC]J=)4X0DE-!#H      /\    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     X 00!0 $X (  M "  40!4 $$ (  M
M "  ,0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @
M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!8            "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$
M)@      #@             _@   .$))30/R       *  #_______\  #A"
M24T$#0      !    %HX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      T$    &              !&    N0
M  8 9P P #0 80 P #0    !                          $
M     +D   !&                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   !&     %)G:'1L;VYG    N0    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    1@    !2
M9VAT;&]N9P   +D    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     ,X0DE-! P     #)     !    BP   #4   &D  !6]
M#'0 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #4
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M=?BV6.&-8;:P8:X@M)^_]U#?W5R,<<XBHQHM<&8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M#'SP@5,7(Y@P?*X#];7Z8N:E0?X3@<D  _USE1PH9!(V@9RG.2 !I$'8[<S
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M,JY!!&0D9"@/'+,H3I6&@:=[AU%B8/*">VV-PD D2#>P 'D PYV%K&3CHG
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MNQ8,+V>WMOCC([/3K4%"P8VMS>+PC&4MS(A=>HK!SG^S1NSCW*4$\#CQ]'W
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M"B&1;H&+2)F)N 8D8-]]GN6>"P?8A]QW&(KVG<@\R;R3)I+V>OI3=2O1^4/
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M/(U^)9"K0HZDU*R   D*)2,Q3>]1 #IID$DAG(:,315-18"R6A!<)!TFF ;
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MO5.DZ0\6(_(VX2WY;SO>,=0Y31 .4X2 .Q[)^=QQ@CC!(R?C)QX^+26V??\
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MKUY!J^A3P 03@ #DX&!C@9P,XYX[\]_"]>G^F'I%C/G]>_6^,FQ(Q@8QV )
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;2N3G.2<_OS^P^,>%@TB[3Y]O\\]\9O!AX__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
